Newly discovered molecule may be a potential therapeutic target for triple-negative breast cancer

Mar 27 2024Hiroshima University Breast cancer is the most common type of cancer, ranking fifth among all cancers in cancer-related deaths. In 2020, there were 2.3 million new cases of breast cancers reported around the globe. In that year, breast cancer caused 685,000 deaths.

Breast cancer is divided into three types. These types, defined mainly by receptor and protein expression, are luminal breast cancer, HER2-positive breast cancer, and triple-negative breast cancer. Triple-negative breast cancer does not have the estrogen receptor, progesterone receptor, or HER2 found in the other two types of breast cancer. Without these receptors, or targets, this cancer is challenging to treat.

Related StoriesThe luminal androgen receptor subtype of triple negative breast cancer has a high expression of the androgen receptor and genes associated with androgenic hormonally-regulated pathways. As a result, researchers have made many attempts to develop new strategies to treat the luminal androgen receptor subtype of triple negative breast cancer with drugs that inhibit the androgen receptor activity.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Newly discovered link between FBXW7 mutations and EGFR signaling in colorectal cancerThe Organoid group at the Hubrecht Institute has identified a new link between FBXW7 mutations and epidermal growth factor receptor (EGFR) signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations have been associated with worse treatment outcomes.
Source: medical_xpress - 🏆 101. / 51 Read more »